Select therapeutic use:
Indications for OMNIPAQUE 240:
For intrathecal administration in adults including myelography (lumbar, thoracic, cervical, total columnar) and in contrast enhancement for computerized tomography (myelography, cisternography, ventriculography). IV: In adults, for contrast enhancement for computed tomographic head imaging and peripheral venography (phlebography). In children, for contrast enhancement for computed tomographic head imaging. Oral/body cavity use: In adults, for arthrography, endoscopic retrograde pancreatography (ERP) and cholangiopancreatography (ERCP), herniography, and hysterosalpingography. In children, for examination of the gastrointestinal tract.
Adults and Children:
See literature for dosing based on procedure.
Local or systemic infection (w. myelography). Concomitant corticosteroids with intrathecal administration. Immediate repeat myelography in the event of technical failure. Hysterosalpingography: during menstrual period or when menstural flow is imminent; genital tract infection, pregnant women.
Do not administer Omnipaque 350 intrathecally: severe reactions may occur (eg, death, convulsion, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, brain edema). To be used by trained personnel in appropriate facilities. History of epilepsy. Severe cardiovascular disease. Chronic alcoholism. Multiple sclerosis. Diabetes. Multiple myeloma. Carcinoma. Resistant anuria. Pheochromocytoma. Homozygous sickle cell disease. Homocystinuria: avoid. Chronic pulmonary emphysema. Thyroid disorder. Patients with evidence of inadvertant intracranial entry of large or concentrated bolus of contrast medium: increased risk of seizures; consider prophylactic barbiturate therapy. Direct intracisternal or ventricular administration for standard radiography: not recommended. Maintain elevation of head during procedure, on the stretcher, or in bed. Avoid excessive and active patient movement or straining. Hepatic or renal impairment. Renal transplant recipients. Elderly. Pregnancy (Cat.B). Nursing mothers: bottle feeding may be substituted for breast feeding for 24hrs following administration.
Radiographic contrast medium.
Concomitant drugs that lower seizure threshold (eg, phenothiazines, MAOIs, tricyclics, CNS stimulants, analeptics, major tranquilizers, antipsychotics): not recommended; discontinue 48hrs and for at least 24hrs post-procedure. May reduce iodine-binding capacity of thyroid tissue for up to 2 weeks.
Intrathecal: headache, backache, neckache, stiffness, GI upset; allergic reactions (may be severe). IV: inj site reactions, arrhythmias, angina/chest pain, hypotension, vertigo, vision abnormalities, headache, taste perversion, GI upset. Body cavities: pain, swelling, heat. Oral: diarrhea, nausea, vomiting, abdominal pain, flatulence, headache; children: also, fever, hypotension, urticaria. Arthrography: joint pain/swelling, heat sensation. ERP/ERCP: transient pain, hypertension, somnolence, burning, GI upset. Hysterosalpingography: transient pain, somnolence, fever, nausea. Herniography: pain, headache, unwell feeling, diarrhea, flatulence.
Omnipaque 240 (200mL)—10; Omnipaque 300 (200mL, 500mL)—10; Omnipaque 350 (500mL)—10